- Home
- RQI vs SRPT Comparison
RQI vs SRPT Comparison
Compare RQI & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | SRPT |
|---|---|---|
| Founded | 2002 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2001 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RQI | SRPT |
|---|---|---|
| Price | $12.18 | $22.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 29 |
| Target Price | N/A | ★ $25.85 |
| AVG Volume (30 Days) | 480.2K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.99 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.78 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $11.30 | $14.68 |
| 52 Week High | $13.57 | $25.32 |
Technical Indicators
Market Signals| Indicator | RQI | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 73.88 |
| Support Level | $11.95 | $15.40 |
| Resistance Level | $12.29 | $23.71 |
| Average True Range (ATR) | 0.12 | 1.34 |
| MACD | -0.02 | 0.44 |
| Stochastic Oscillator | 34.90 | 93.98 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. The Fund's secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.